13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002077247
Total reported value
$629.9M
$629.9M
23 檔
27.1%
According to the latest 13F quarterly dataset, Trails Edge Capital Partners, LP managed an equity portfolio of $629.9M at the end of Q4 2025, spanning 23 distinct U.S. exchange-listed positions.
During Q4 2025, Trails Edge Capital Partners, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 9.37% | — | — | |
| 2 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 8.50% | — | — | |
| 3 | PCVX | Vaxcyte Inc | Stock-Other | 8.41% | -8.82% | EXIT | |
| 4 | NRIX | Nurix Therapeutics Inc | Stock-Other | 8.17% | -0.13% | — | |
| 5 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 7.68% | +0.40% | — | |
| 6 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 6.61% | -4.31% | — | |
| 7 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 5.85% | +0.65% | — | |
| 8 | RCUS | Arcus Biosciences Inc | Stock-Other | 5.40% | -5.19% | EXIT | |
| 9 | TYRA | Tyra Biosciences Inc | Stock-Other | 4.55% | — | — | |
| 10 | NGNE | Neurogene Inc | Stock-Other | 4.00% | -0.05% | — | |
| 11 | AM6 | Amicus Therapeutics Inc | Stock-Other | 3.67% | — | — | |
| 12 | APGE | Apogee Therapeutics Inc | Stock-Other | 3.58% | — | — | |
| 13 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 3.13% | -0.18% | — | |
| 14 | IVA | Inventiva SA - Adr | Stock-Other | 3.05% | -1.78% | — | |
| 15 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 3.00% | -0.62% | — | |
| 16 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.99% | — | — | |
| 17 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 2.54% | -0.52% | — | |
| 18 | MBX | Mbx Biosciences Inc | Stock-Other | 2.46% | — | — | |
| 19 | VTVT | Vtv Therapeutics Inc- Cl A | Stock-Other | 2.28% | -0.76% | — | |
| 20 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.88% | — | — | |
| 21 | IMVT | Immunovant Inc | Stock-Other | 1.51% | -2.36% | EXIT | |
| 22 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 23 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.62% | -2.90% | — |
According to official SEC Form 13F filings, Trails Edge Capital Partners, LP reported a total U.S. public equity portfolio value of $629.9M across 23 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACAD, BRD1EUR, PCVX) accounted for 27.1% of total reported equity market value during Q4 2025.
During Q4 2025, Trails Edge Capital Partners, LP's top holdings by market value included ACAD (9.4%)、BRD1EUR (8.5%)、PCVX (8.4%). The largest single position, ACAD, represented 9.4% of total portfolio value.
In Q4 2025, Trails Edge Capital Partners, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.